# Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years

> **NCT01235975** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 400 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Meningococcal vaccine GSK 134612
- **BIOLOGICAL:** MencevaxACWY TM

## Key facts

- **NCT ID:** NCT01235975
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-30
- **Primary completion:** 2011-07-29
- **Final completion:** 2011-08-03
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235975, "Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01235975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*